Chronoscale Holdings Corp quarterly report, Q1 FY2026

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Designs and markets exoskeleton technology for healthcare (neurorehabilitation) and industrial markets. The company is currently pursuing a business combination with Applied Digital Cloud Corporation (ChronoScale), which, if consummated, will result in a name change to ChronoScale Corporation and a fiscal year-end change to May 31.

Key Financial Metrics

Metric Q1 2026 Q1 2025
Revenue $2.14 million $3.38 million
Gross Profit $1.07 million $1.81 million
Gross Margin 50% 54%
Net Loss $(6.89) million $(2.89) million
Net Loss Per Share (Basic/Diluted) $(2.04) $(1.84)
Cash and Restricted Cash $4.0 million $8.05 million
Working Capital $5.0 million $5.4 million
Total Debt (Current + Non-Current) ~$4.85 million ~$4.0 million

Note: Debt includes B. Riley Promissory Note ($2.08M), Parker Hannifin Note ($1.77M), and other notes/leases.

Material Changes vs. Prior Period

  • Revenue Decline: Revenue decreased 37% year-over-year, driven by lower volume in Enterprise Health device sales across all regions (Americas, EMEA, APAC).
  • Increased Operating Expenses: Total operating expenses rose 28% to $6.69 million. General and Administrative (G&A) expenses increased 59% primarily due to legal costs associated with the proposed Business Combination. Sales and Marketing expenses increased 20% due to higher bad debt expense ($0.3 million) from a single counterparty.
  • Warrant Liability Revaluation: The company recorded a $0.73 million loss on the revaluation of warrant liabilities, compared to a negligible gain in the prior year. This is a non-cash charge driven by changes in stock price and volatility.
  • Foreign Exchange: Unrealized foreign exchange loss of $0.24 million in Q1 2026, compared to a gain of $0.63 million in Q1 2025.
  • Financing Activity: In January 2026, the company completed a private placement raising net proceeds of approximately $5.3 million via Series B Convertible Preferred Stock and warrants.

Outlook, Risks, and Management Commentary

  • Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the filing date. Cash on hand is estimated to fund operations only into the early part of Q3 2026. Additional financing is required.
  • Business Combination: The proposed merger with Applied Digital Cloud is subject to conditions, including raising at least $15 million in cash. If the deal fails, the company faces significant liquidity risks and potential dilution from future fundraising.
  • Revenue Strategy: Management expects 2026 revenue to remain primarily driven by Enterprise Health sales, with Personal Health (Ekso Indego Personal) contributing incrementally as Medicare reimbursement processes are refined.
  • Cost Reduction: The company is pursuing cost reduction efforts, delaying product development, and refocusing sales to align expenses with available cash, though success is not guaranteed.

Investor Verification Checklist

  • Liquidity Runway: Verify the timeline for the next financing round given the "early Q3 2026" cash runway estimate.
  • Business Combination Status: Monitor progress on the $15 million cash condition and regulatory approvals for the Applied Digital Cloud merger.
  • Bad Debt Exposure: Assess the collectability of the specific customer account that triggered the $0.3 million bad debt charge.
  • Warrant Liability Volatility: Review the impact of stock price fluctuations on the recurring non-cash warrant liability revaluation charges.
  • Debt Covenants: Confirm compliance with covenants on the B. Riley Promissory Note (due Sept 2026) and Parker Hannifin Note.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.